SecBot SecBot
6-K ·Filed May 7, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001193125-26-210386
Notable filing: 6-K
Actionable Insight ▲ Bullish

The massive YORVIPATH revenue beat and first-ever operating profit mark a fundamental inflection point. The convertible note conversion eliminates a large overhang and the PRV sale adds cash. Watch for YUVIWEL enrollment trajectory and EU regulatory decision in Q4 2026 as the next catalysts. The oncology discontinuation is a minor negative but strategically sound.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$246.14
T+0 close · May 7, 2026 · via day close
Latest settled
−1.09%
T+60 · $243.45
Vs SPY
−4.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $246.14entry
  2. T+1 · 6mo ago −3.04%α −3.87% · $238.66
  3. T+5 · 6mo ago −1.04%α −2.54% · $243.58
  4. T+20 · 5mo ago −11.92%α −15.06% · $216.79
  5. T+60 · 3mo ago −1.09%α −4.93% · $243.45

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sales of €197M. The company achieved its first-ever operating profit of €25M (vs. a €104M loss in Q1 2025) and a non-IFRS operating profit of €55M. Net profit of €629M included a €679M deferred tax asset recognition; non-IFRS net profit was €18M. Subsequent events include the conversion of $575M convertible notes into 3.6M ordinary shares and a $187.5M PRV sale agreement.

Key Facts

  • Q1 2026 total revenue €247M vs €101M YoY (+144%)
  • YORVIPATH revenue €197M vs €45M YoY (+341%)
  • SKYTROFA revenue €44M vs €51M YoY (-14%)
  • Operating profit €25M vs loss of €104M YoY
  • Non-IFRS operating profit €55M vs loss of €79M YoY
  • Non-IFRS net profit €18M vs loss of €73M YoY
  • Net profit €629M includes €679M deferred tax asset recognition
  • Cash and equivalents €573M as of March 31, 2026
  • Converted all $575M 2.25% convertible notes due 2028 into 3,635,813 ordinary shares on May 6, 2026
  • Agreed to sell Rare Pediatric Disease PRV for $187.5M cash
  • YUVIWEL launched in U.S. with >60 patient enrollments as of May 1, 2026
  • Discontinued internal development of TransCon IL-2/oncology program

Financial Impact

Revenue more than doubled YoY to €247M; operating income swung from -€104M to +€25M; non-IFRS operating profit margin 22.4%; $187.5M PRV sale and $575M convertible note conversion strengthen balance sheet

revenueoperating incomenet incomecash positiondilution

Risk Factors

  • SKYTROFA revenue declining 14% YoY signals potential market share loss
  • SG&A expenses rose 44% YoY to €145M, pressuring margins
  • Operating cash flow still negative at -€8M despite revenue growth
  • Dilution from convertible note conversion adds 3.6M shares
  • EU approval for YUVIWEL not guaranteed and could be delayed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-210386
Document: d121855d6k.htm0001193125-26-210386
Document: 0001193125-26-210386-index-headers.html0001193125-26-210386
Document: 0001193125-26-210386-index.html0001193125-26-210386
Document: 0001193125-26-210386.txt0001193125-26-210386

Track record

41 reports on ASND

Performance horizon

14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $267.07 Now $271.73 +1.74% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Tue (17h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026